Latest News and Press Releases

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

Research & Development Highlights: In January of 2022, announced positive topline results from Phase 2 EMPATHY clinical trial of ensovibep for the treatment of non-hospitalized COVID-19 patients,...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

Agreement grants global rights of ensovibep to Novartis, who will lead further development and commercialization of the programFinancial terms include milestone payment of CHF150 million to Molecular...

ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

Topline results from the randomized, placebo-controlled EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...